Lummy(SZ:300006) Sou Hu Cai Jing·2025-08-04 08:21Core Insights - The stock price of Lai Mei Pharmaceutical (300006) closed at 5.6 yuan, up 4.67% with a turnover rate of 10.24% and a trading volume of 1.0816 million lots, amounting to 574 million yuan [1] - The company reported a total revenue of 198 million yuan for Q1 2025, representing a year-on-year growth of 9.54%, while the net profit attributable to shareholders decreased by 201.08% to 13.7753 million yuan [1] - Lai Mei Pharmaceutical has made investments in 27 companies and participated in 1,479 bidding projects, holding 207 trademark registrations and 238 patents [2] Financial Performance - Total revenue for Q1 2025: 198 million yuan, up 9.54% year-on-year [1] - Net profit attributable to shareholders: 13.7753 million yuan, down 201.08% year-on-year [1] - Non-recurring net profit: 14.2911 million yuan, down 92.25% year-on-year [1] - Current ratio: 2.459, quick ratio: 2.157, debt-to-asset ratio: 29.09% [1] Company Overview - Lai Mei Pharmaceutical Co., Ltd. was established in 1999 and is located in Chongqing, primarily engaged in the pharmaceutical manufacturing industry [1] - The registered capital of the company is 1.055911205 billion yuan, with paid-in capital of 428.854034 million yuan [1] - The legal representative of the company is Liang Jiansheng [1]